Drugs / ZSNeo-DC
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04968366 | Jul 2021 → Apr 2024 | brain glioblastoma | Beijing Tiantan Hospital | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZSNeo-DC | “Here, we present the results of a single-arm, open-label phase 1b trial on neoantigen-pulsed autologous dendritic cells (ZSNeo-DC) as an adjuvant treatment for nGBM” PMID 42401550 ↗ Jul 2026 |
| Modality | Cell therapy | “neoantigen-pulsed autologous dendritic cells (ZSNeo-DC) as an adjuvant treatment for nGBM” PMID 42401550 ↗ Jul 2026 |
| Route | Other | “Eleven patients with nGBM received intradermal administration of ZSNeo-DC following surgery and standard radio-chemotherapy” PMID 42401550 ↗ Jul 2026 |